Jyong Biotech Ltd
jyongbio.comWhat Do They Do?
Develops plant-derived drug candidates for urinary system diseases, including benign prostate conditions, prostate cancer prevention and interstitial cystitis.
20-F for FY2025, filed May 15, 2026We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and…View ↗
Our pipeline features three innovative and differentiated new drug candidates, and we are developing them for (i) the treatment of benign…View ↗
Botreso®: Botreso® is our new botanical drug candidate developed for treatment of BPH/LUTS. Botreso® is expected to be our core product in…View ↗
PCP: PCP is our new botanical drug candidate developed for the prevention of prostate cancer. PCP, like Botreso®, contains patented active…View ↗
IC: Interstitial Cystitis (IC) is our additional key new drug candidate which is composed of polysorbate loaded micelles as nanocarriers…View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2025, filed May 15, 2026
Loading...
